A型肉毒毒素在瘢痕治疗中的临床应用及机制探讨

章一新; 张书诺

doi:10.3760/cma.j.cn501120-20210701-00232

A型肉毒毒素在瘢痕治疗中的临床应用及机制探讨

doi: 10.3760/cma.j.cn501120-20210701-00232

章一新^,,
张书诺

上海交通大学医学院附属第九人民医院整复外科　　200011

基金项目:

国家自然科学基金面上项目 81772098

国家自然科学基金青年科学基金项目 81801917, 81801918

上海市教委高峰高原计划—“研究型医师”项目 20152227

上海市科学技术委员会优秀技术带头人计划 18XD1423700

上海交通大学医学院附属第九人民医院临床研究型多学科诊疗团队建设项目 2017-1-007

上海交通大学医学院附属第九人民医院临床研究助推计划 JYLJ027

详细信息

通讯作者:
章一新，Email：zhangyixin6688@163.com

计量
- 文章访问数: 307
- HTML全文浏览量: 60
- PDF下载量: 36
- 被引次数: 0
出版历程
- 收稿日期: 2021-07-01

Clinical application and mechanism of botulinum toxin type A in scar treatment

Zhang Yixin^,,
Zhang Shunuo

Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China

Funds:

General Program of National Natural Science Foundation of China 81772098

Youth Program of National Natural Science Foundation of China 81801917, 81801918

Peak Plateau Plan of Shanghai Education Commission "Research Doctors" Project of China 20152227

Excellent Technology Leader Plan of Shanghai Science and Technology Commission of China 18XD1423700

Construction Project of Clinical Research Multidisciplinary Diagnosis and Treatment Team of Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine 2017-1-007

Clinical Research Booster Program of Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine JYLJ027

More Information

Corresponding author: Zhang Yixin, Email: zhangyixin6688@163.com

摘要

摘要: 病理性瘢痕不仅会引起局部躯体不适，更会对患者的心理产生影响。随着研究的深入，目前A型肉毒毒素（BTX-A）已被逐渐应用于瘢痕的临床治疗。本文归纳了BTX-A在瘢痕治疗中早期减张、抑制结缔组织增生、减轻皮肤炎症这3种作用机制，并总结了其在不同类型瘢痕治疗中的临床应用。但目前尚未对BTX-A注射治疗瘢痕的时间、方式及配比制订统一标准，并缺乏长期随访结果，未来需更深入探讨，以明确BTX-A抑制瘢痕的机制，并制订统一的BTX-A注射治疗标准，为瘢痕提供更有效的治疗方案。
- 瘢痕 /
- A型肉毒毒素 /
- 局部注射治疗
Abstract: Pathological scars cause both local physical discomforts and mental disorders for patients. With the development of research, botulinum toxin type A (BTX-A) has been gradually used in the clinical treatment of scars. This article summarizes three potential mechanisms of BTX-A, including early tension reduction, inhibition of connective tissue hyperplasia, and alleviation of skin inflammation, as well as the clinical application of BTX-A in treating different types of scars. However, at present there is no uniform standard for the time, method, and proportioning of BTX-A injection for scar treatment, and there is also a lack of long-term follow-up results. Further researches are needed in future to clarify the mechanism of BTX-A in inhibiting scars, establish a uniform protocol of BTX-A injection, and provide a more effective treatment plan for scars.
- Cicatrix /
- Botulinum toxins, type A /
- Local injection treatment
所有作者均声明不存在利益冲突

HTML全文

参考文献(59)

[1]	GauglitzGG,KortingHC,PavicicT,et al.Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies[J].Mol Med,2011,17(1/2):113-125.DOI: 10.2119/molmed.2009.00153.
[2]	RabelloFB, SouzaCD, Farina JúniorJA. Update on hypertrophic scar treatment[J]. Clinics (Sao Paulo), 2014, 69(8): 565-573. DOI: 10.6061/clinics/2014(08)11.
[3]	LeeSH,MinHJ,KimYW,et al.The efficacy and safety of early postoperative botulinum toxin A injection for facial scars[J].Aesthetic Plast Surg,2018,42(2):530-537.DOI: 10.1007/s00266-017-1008-7.
[4]	HuL,ZouY,ChangSJ,et al.Effects of botulinum toxin on improving facial surgical scars: a prospective, split-scar, double-blind, randomized controlled trial[J].Plast Reconstr Surg,2018,141(3):646-650.DOI: 10.1097/PRS.0000000000004110.
[5]	KimSH,LeeSJ,LeeJW,et al.Clinical trial to evaluate the efficacy of botulinum toxin type A injection for reducing scars in patients with forehead laceration: a double-blinded, randomized controlled study[J].Medicine (Baltimore),2019,98(34):e16952.DOI: 10.1097/MD.0000000000016952.
[6]	KostrzewaRM,Segura-AguilarJ.Botulinum neurotoxin: evolution from poison, to research tool--onto medicinal therapeutic and future pharmaceutical panacea[J].Neurotox Res,2007,12(4):275-290.DOI: 10.1007/BF03033911.
[7]	TruongDD,JostWH.Botulinum toxin: clinical use[J].Parkinsonism Relat Disord,2006,12(6):331-355.DOI: 10.1016/j.parkreldis.2006.06.002.
[8]	Peng ChenZ, MorrisJG, RodriguezRL, et al. Emerging opportunities for serotypes of botulinum neurotoxins[J]. Toxins (Basel), 2012, 4(11): 1196-1222.DOI: 10.3390/toxins4111196.
[9]	PhillipsTJ,FungE,RigbyMH,et al.The use of botulinum toxin type A in the healing of thyroidectomy wounds: a randomized, prospective, placebo-controlled study[J].Plast Reconstr Surg,2019,143(2):375e-381e.DOI: 10.1097/PRS.0000000000005264.
[10]	GrandoSA,ZacharyCB.The non-neuronal and nonmuscular effects of botulinum toxin: an opportunity for a deadly molecule to treat disease in the skin and beyond[J].Br J Dermatol,2018,178(5):1011-1019.DOI: 10.1111/bjd.16080.
[11]	BonaparteJP,EllisD.Alterations in the elasticity, pliability, and viscoelastic properties of facial skin after injection of onabotulinum toxin A[J].JAMA Facial Plast Surg,2015,17(4):256-263.DOI: 10.1001/jamafacial.2015.0376.
[12]	RoseAE,GoldbergDJ.Safety and efficacy of intradermal injection of botulinum toxin for the treatment of oily skin[J].Dermatol Surg,2013,39(3 Pt 1):443-448.DOI: 10.1111/dsu.12097.
[13]	ShahAR.Use of intradermal botulinum toxin to reduce sebum production and facial pore size[J].J Drugs Dermatol,2008,7(9):847-850.
[14]	MinP,XiW,GrassettiL,et al.Sebum production alteration after botulinum toxin type A injections for the treatment of forehead rhytides: a prospective randomized double-blind dose-comparative clinical investigation[J].Aesthet Surg J,2015,35(5):600-610.DOI: 10.1093/asj/sju150.
[15]	MessikhR,AtallahL,AubinF,et al.Botulinum toxin in disabling dermatological diseases[J].Ann Dermatol Venereol,2009,136 Suppl 4:S129-136.DOI: 10.1016/S0151-9638(09)74540-5.
[16]	CampanatiA,MartinaE,GiuliodoriK,et al.Botulinum toxin off-label use in dermatology: a review[J].Skin Appendage Disord,2017,3(1):39-56.DOI: 10.1159/000452341.
[17]	GassnerHG,SherrisDA,OtleyCC.Treatment of facial wounds with botulinum toxin A improves cosmetic outcome in primates[J].Plast Reconstr Surg,2000,105(6):1948-1953; discussion 1954-1955.DOI: 10.1097/00006534-200005000-00005.
[18]	JablonkaEM,SherrisDA,GassnerHG.Botulinum toxin to minimize facial scarring[J].Facial Plast Surg,2012,28(5):525-535.DOI: 10.1055/s-0032-1325641.
[19]	MatakI,LackovićZ.Botulinum neurotoxin type A: actions beyond SNAP-25?[J].Toxicology,2015,335:79-84.DOI: 10.1016/j.tox.2015.07.003.
[20]	GassnerHG,BrissettAE,OtleyCC,et al.Botulinum toxin to improve facial wound healing: a prospective, blinded, placebo-controlled study[J].Mayo Clin Proc,2006,81(8):1023-1028.DOI: 10.4065/81.8.1023.
[21]	ZiadeM,DomergueS,BatifolD,et al.Use of botulinum toxin type A to improve treatment of facial wounds: a prospective randomised study[J].J Plast Reconstr Aesthet Surg,2013,66(2):209-214.DOI: 10.1016/j.bjps.2012.09.012.
[22]	ChangCS,WallaceCG,HsiaoYC,et al.Botulinum toxin to improve results in cleft lip repair: a double-blinded, randomized, vehicle-controlled clinical trial[J].PLoS One,2014,9(12):e115690.DOI: 10.1371/journal.pone.0115690.
[23]	HuangRL,HoCK,TrempM,et al.Early postoperative application of botulinum toxin type A prevents hypertrophic scarring after epicanthoplasty: a split-face, double-blind, randomized trial[J].Plast Reconstr Surg,2019,144(4):835-844.DOI: 10.1097/PRS.0000000000006069.
[24]	何永强.A型肉毒毒素联合减张压迫法在面部整形切口的应用[J].中国医疗美容,2015,5(4):43-45.
[25]	吴亚龙.A型肉毒素联合减张力压迫法在头面部手术中的应用价值探析[J].中国实用医药,2016,11(26):242-243.DOI: 10.14163/j.cnki.11-5547/r.2016.26.157.
[26]	乔向坤.A型肉毒毒素联合持续减张法在面部小面积瘢痕手术切口中的应用效果观察[J].中国医疗美容,2017,7(12):34-37.DOI: 10.19593/j.issn.2095-0721.2017.12.014.
[27]	陶谏,刘宾,汪阳,等.A型肉毒毒素对减轻额部术后瘢痕增生的临床研究[J].陕西医学杂志,2018,47(8):1011-1013.DOI: 10.3969/j.issn.1000-7377.2018.08.018.
[28]	ZhuZ,DingJ,TredgetEE.The molecular basis of hypertrophic scars[J/OL].Burns Trauma,2016,4:2[2021-07-01].https://pubmed.ncbi.nlm.nih.gov/27574672/.DOI: 10.1186/s41038-015-0026-4.
[29]	KimS,AhnM,PiaoY,et al.Effect of botulinum toxin type A on TGF-β/Smad pathway signaling: implications for silicone-induced capsule formation[J].Plast Reconstr Surg,2016,138(5):821e-829e.DOI: 10.1097/PRS.0000000000002625.
[30]	ParkTH,ParkJH,ChangCH,et al.Botulinum toxin A upregulates Rac1, Cdc42, and RhoA gene expression in a dose-dependent manner: in vivo and in vitro study[J].J Craniofac Surg,2016,27(2):516-520.DOI: 10.1097/SCS.0000000000002272.
[31]	JeongHS,LeeBH,SungHM,et al.Effect of botulinum toxin type A on differentiation of fibroblasts derived from scar tissue[J].Plast Reconstr Surg,2015,136(2):171e-178e.DOI: 10.1097/PRS.0000000000001438.
[32]	XiaoxueW,XiC,ZhiboX.Effects of botulinum toxin type A on expression of genes in keloid fibroblasts[J].Aesthet Surg J,2014,34(1):154-159.DOI: 10.1177/1090820X13482938.
[33]	颜彤彤,陈敏亮,马奎,等.A型肉毒毒素对成纤维细胞中α平滑肌肌动蛋白和肌球蛋白-Ⅱ表达的影响[J].中华整形外科杂志,2014,30(2):118-121.DOI: 10.3760/cma.j.issn.1009-4598.2014.02.010.
[34]	ChenM,YanT,MaK,et al.Botulinum toxin type A inhibits α-smooth muscle actin and myosin Ⅱ expression in fibroblasts derived from scar contracture[J].Ann Plast Surg,2016,77(3):e46-49.DOI: 10.1097/SAP.0000000000000268.
[35]	WuWS,WangFS,YangKD,et al.Dexamethasone induction of keloid regression through effective suppression of VEGF expression and keloid fibroblast proliferation[J].J Invest Dermatol,2006,126(6):1264-1271.DOI: 10.1038/sj.jid.5700274.
[36]	AndrewsJP,MarttalaJ,MacarakE,et al.Keloids: the paradigm of skin fibrosis-pathomechanisms and treatment[J].Matrix Biol,2016,51:37-46.DOI: 10.1016/j.matbio.2016.01.013.
[37]	VillaniA,Carmela AnnunziataM,Antonietta LucianoM,et al.Skin needling for the treatment of acne scarring: a comprehensive review[J].J Cosmet Dermatol,2020,19(9):2174-2181.DOI: 10.1111/jocd.13577.
[38]	Morelli CoppolaM,SalzilloR,SegretoF,et al.Triamcinolone acetonide intralesional injection for the treatment of keloid scars: patient selection and perspectives[J].Clin Cosmet Investig Dermatol,2018,11:387-396.DOI: 10.2147/CCID.S133672.
[39]	XiaoZ,ZhangF,CuiZ.Treatment of hypertrophic scars with intralesional botulinum toxin type A injections: a preliminary report[J].Aesthetic Plast Surg,2009,33(3):409-412.DOI: 10.1007/s00266-009-9334-z.
[40]	ShaarawyE,HegazyRA,Abdel HayRM.Intralesional botulinum toxin type A equally effective and better tolerated than intralesional steroid in the treatment of keloids: a randomized controlled trial[J].J Cosmet Dermatol,2015,14(2):161-166.DOI: 10.1111/jocd.12134.
[41]	刘斌,李静,胡惠清.A型肉毒素治疗瘢痕增生的疗效和安全性分析[J].中国中西医结合皮肤性病学杂志,2017,16(1):25-27.DOI: 10.3969/j.issn.1672-0709.2017.01.006.
[42]	闫成祥,王喜梅,张亚茹.A型肉毒素治疗面部瘢痕疙瘩的效果分析[J].河南医学研究,2018,27(9):1594-1596.DOI: 10.3969/j.issn.1004-437X.2018.09.024.
[43]	羊乃康,孙琦.A型肉毒毒素与曲安奈德治疗瘢痕疙瘩的疗效和安全性比较[J].中国美容医学,2020,29(5):66-69.DOI: 10.15909/j.cnki.cn61-1347/r.003694.
[44]	PruksapongC,YingtaweesittikulS,BurusapatC.Efficacy of botulinum toxin A in preventing recurrence keloids: double blinded randomized controlled trial study: intraindividual subject[J].J Med Assoc Thai,2017,100(3):280-286.
[45]	MinP,ZhangZ,GrassettiL,et al.Alteration of skin mechanical properties in patients undergoing botulinum toxin type A injections of forehead rhytides[J].Aesthetic Plast Surg,2016,40(3):410-420.DOI: 10.1007/s00266-016-0629-6.
[46]	OgawaR.Keloid and hypertrophic scars are the result of chronic inflammation in the reticular dermis[J].Int J Mol Sci,2017,18(3):606.DOI: 10.3390/ijms18030606.
[47]	AkaishiS,OgawaR,HyakusokuH.Keloid and hypertrophic scar: neurogenic inflammation hypotheses[J].Med Hypotheses,2008,71(1):32-38.DOI: 10.1016/j.mehy.2008.01.032.
[48]	WangPH,HuangBS,HorngHC,et al.Wound healing[J].J Chin Med Assoc,2018,81(2):94-101.DOI: 10.1016/j.jcma.2017.11.002.
[49]	WangXQ,KravchukO,WinterfordC,et al.The correlation of in vivo burn scar contraction with the level of α-smooth muscle actin expression[J].Burns,2011,37(8):1367-1377.DOI: 10.1016/j.burns.2011.07.018.
[50]	ZegarskaB,LelińskaA,TyrakowskiT.Clinical and experimental aspects of cutaneous neurogenic inflammation[J].Pharmacol Rep,2006,58(1):13-21.
[51]	PietramaggioriG,LiuP,SchererSS,et al.Tensile forces stimulate vascular remodeling and epidermal cell proliferation in living skin[J].Ann Surg,2007,246(5):896-902.DOI: 10.1097/SLA.0b013e3180caa47f.
[52]	LiYH,YangJ,ZhengZ,et al.Botulinum toxin type A attenuates hypertrophic scar formation via the inhibition of TGF-β1/Smad and ERK pathways[J].J Cosmet Dermatol,2021,20(5):1374-1380.DOI: 10.1111/jocd.13842.
[53]	AustinE,KooE,JagdeoJ.The cellular response of keloids and hypertrophic scars to botulinum toxin A: a comprehensive literature review[J].Dermatol Surg,2018,44(2):149-157.DOI: 10.1097/DSS.0000000000001360.
[54]	LiYH,YangJ,LiuJQ,et al.A randomized, placebo-controlled, double-blind, prospective clinical trial of botulinum toxin type A in prevention of hypertrophic scar development in median sternotomy wound[J].Aesthetic Plast Surg,2018,42(5):1364-1369.DOI: 10.1007/s00266-018-1187-x.
[55]	KimYS,LeeHJ,ChoSH,et al.Early postoperative treatment of thyroidectomy scars using botulinum toxin: a split-scar, double-blind randomized controlled trial[J].Wound Repair Regen,2014,22(5):605-612.DOI: 10.1111/wrr.12204.
[56]	RasaiiS,SohrabianN,GianfaldoniS,et al.Intralesional triamcinolone alone or in combination with botulinium toxin A is ineffective for the treatment of formed keloid scar: a double blind controlled pilot study[J].Dermatol Ther,2019,32(2):e12781.DOI: 10.1111/dth.12781.
[57]	朱加伟.手术切除联合A型肉毒素和得宝松局部注射治疗瘢痕疙瘩的临床研究[J].世界最新医学信息文摘,2018,18(14):112.DOI: 10.19613/j.cnki.1671-3141.2018.14.086.
[58]	赵媛媛,申琳.A型肉毒素注射在治疗瘢痕疙瘩顽固性痛痒中的应用[J].中国妇幼健康研究,2016,27(2):54-55.
[59]	张琼玲,陈锦安,夏建兵.A型肉毒素注射治疗瘢痕疙瘩顽固性痛痒的临床研究[J].中国医疗美容,2017,7(9):19-21.DOI: 10.19593/j.issn.2095-0721.2017.09.008.